Pinebridge Investments L.P. Raises Stock Position in Amedisys, Inc. (NASDAQ:AMED)

Pinebridge Investments L.P. increased its holdings in shares of Amedisys, Inc. (NASDAQ:AMED) by 40.7% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 15,118 shares of the health services provider’s stock after purchasing an additional 4,374 shares during the period. Pinebridge Investments L.P.’s holdings in Amedisys were worth $1,373,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in the stock. Blue Trust Inc. boosted its position in shares of Amedisys by 55.1% in the fourth quarter. Blue Trust Inc. now owns 349 shares of the health services provider’s stock worth $34,000 after buying an additional 124 shares during the period. HBW Advisory Services LLC acquired a new position in Amedisys during the 4th quarter worth approximately $38,000. Versant Capital Management Inc boosted its holdings in Amedisys by 68.5% in the 4th quarter. Versant Capital Management Inc now owns 450 shares of the health services provider’s stock worth $41,000 after acquiring an additional 183 shares during the period. Vestcor Inc acquired a new stake in Amedisys in the fourth quarter valued at approximately $73,000. Finally, Venturi Wealth Management LLC raised its stake in shares of Amedisys by 397.4% during the fourth quarter. Venturi Wealth Management LLC now owns 975 shares of the health services provider’s stock valued at $89,000 after purchasing an additional 779 shares during the period. 94.36% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on AMED. Royal Bank of Canada reaffirmed an “outperform” rating and set a $100.00 price target on shares of Amedisys in a report on Wednesday, April 16th. Stephens reaffirmed an “equal weight” rating and set a $101.00 target price on shares of Amedisys in a research report on Tuesday, March 4th. Four investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $100.75.

Amedisys Price Performance

Shares of AMED stock opened at $94.50 on Monday. The firm has a market cap of $3.10 billion, a P/E ratio of 37.50, a P/E/G ratio of 1.78 and a beta of 0.89. The firm has a fifty day moving average of $92.21 and a two-hundred day moving average of $91.75. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.19 and a quick ratio of 1.19. Amedisys, Inc. has a 1-year low of $82.15 and a 1-year high of $98.95.

Amedisys (NASDAQ:AMED) last announced its quarterly earnings data on Wednesday, April 23rd. The health services provider reported $1.25 earnings per share for the quarter, beating the consensus estimate of $1.13 by $0.12. Amedisys had a return on equity of 12.20% and a net margin of 3.57%. The firm had revenue of $594.78 million during the quarter, compared to analyst estimates of $597.43 million. As a group, research analysts anticipate that Amedisys, Inc. will post 4.4 earnings per share for the current fiscal year.

Amedisys Company Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.